Axxcess Wealth Management LLC reduced its stake in shares of Nutanix, Inc. (NASDAQ:NTNX - Free Report) by 21.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,729 shares of the technology company's stock after selling 4,991 shares during the period. Axxcess Wealth Management LLC's holdings in Nutanix were worth $1,146,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Harbour Investments Inc. increased its holdings in Nutanix by 2,612.5% in the 4th quarter. Harbour Investments Inc. now owns 434 shares of the technology company's stock valued at $27,000 after purchasing an additional 418 shares in the last quarter. Larson Financial Group LLC increased its stake in Nutanix by 122.7% during the third quarter. Larson Financial Group LLC now owns 510 shares of the technology company's stock valued at $30,000 after purchasing an additional 281 shares during the last quarter. Allworth Financial LP raised its stake in Nutanix by 123.1% during the fourth quarter. Allworth Financial LP now owns 464 shares of the technology company's stock worth $31,000 after acquiring an additional 256 shares during the period. Advisors Asset Management Inc. grew its holdings in shares of Nutanix by 150.7% during the third quarter. Advisors Asset Management Inc. now owns 534 shares of the technology company's stock valued at $32,000 after purchasing an additional 321 shares during the last quarter. Finally, Principal Securities Inc. boosted its holdings in shares of Nutanix by 52.4% during the fourth quarter. Principal Securities Inc. now owns 579 shares of the technology company's stock valued at $35,000 after acquiring an additional 199 shares during the period. 85.25% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, CEO Rajiv Ramaswami sold 95,852 shares of the business's stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $70.00, for a total transaction of $6,709,640.00. Following the completion of the transaction, the chief executive officer now owns 540,463 shares of the company's stock, valued at approximately $37,832,410. The trade was a 15.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Groen Max Pieter De sold 5,500,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $74.51, for a total value of $409,805,000.00. Following the transaction, the director now owns 11,354,032 shares of the company's stock, valued at approximately $845,988,924.32. This trade represents a 32.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,603,146 shares of company stock worth $417,065,856 in the last quarter. 6.80% of the stock is currently owned by company insiders.
Nutanix Trading Down 0.1 %
Nutanix stock traded down $0.05 during trading hours on Tuesday, reaching $74.92. 1,823,383 shares of the company were exchanged, compared to its average volume of 2,436,119. The stock has a 50-day moving average of $69.77 and a 200 day moving average of $66.07. Nutanix, Inc. has a 12 month low of $43.35 and a 12 month high of $79.99. The firm has a market cap of $19.98 billion, a price-to-earnings ratio of -214.06, a PEG ratio of 11.80 and a beta of 1.04.
Analysts Set New Price Targets
NTNX has been the topic of a number of recent analyst reports. Royal Bank of Canada lifted their price target on Nutanix from $83.00 to $95.00 and gave the company an "outperform" rating in a report on Thursday, February 27th. Morgan Stanley boosted their price target on Nutanix from $78.00 to $85.00 and gave the stock an "overweight" rating in a research report on Tuesday, December 17th. Barclays set a $94.00 price target on Nutanix and gave the company an "overweight" rating in a report on Thursday, February 27th. Northland Securities upgraded shares of Nutanix from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $77.00 to $97.00 in a report on Thursday, February 27th. Finally, Oppenheimer raised their price objective on shares of Nutanix from $90.00 to $100.00 and gave the company an "outperform" rating in a research note on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Nutanix presently has a consensus rating of "Buy" and an average target price of $87.79.
View Our Latest Analysis on Nutanix
About Nutanix
(
Free Report)
Nutanix, Inc engages in the provision of a cloud platform leveraging web-scale engineering and consumer-grade design. It operates through the following geographic segments: United States, Europe, the Middle East, Africa, Asia Pacific, and Other Americas. The firm also provides software solutions and cloud services to customers' enterprise infrastructure.
Featured Articles

Before you consider Nutanix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutanix wasn't on the list.
While Nutanix currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.